Clinical Trial Update: A Multiple Ascending Dose Study of Pegozafermin in Participants With Biopsy Confirmed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASH [Phase 1, Phase 2]

View source ↗

Summary

A multiple ascending dose study of pegozafermin in participants with biopsy-confirmed NASH or NAFLD at high risk of NASH has completed phases 1 and 2, with resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Fatty Liver Disease
• Nonalcoholic Steatohepatitis

Drugs mentioned

• Pegozafermin (pegozafermin)

Snippet

Sponsor: 89bio, Inc. | Conditions: NASH | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-04-02